Skinvisible Receives European Patent Notice for Invisicare

Drug Delivery Technology Protected on Four Continents

LAS VEGAS, Nevada. September 22, 2011 - Skinvisible Pharmaceuticals, Inc. (SKVI: OTCQB & OTCBB) announced today that the European Patent Office (EPO) has issued a Notice of Intent to Grant European patent application number 02752847.0 pertaining to Skinvisible's drug delivery system, Invisicare, which is a drug delivery technology used in prescription, over-the-counter and cosmeceutical products. The comprehensive patent protects Invisicare in three main areas: its composition, its method of combining polymers to make the Invisicare complex and the skin / medical conditions Invisicare is used for. This patent provides protection with claims that were also patented in the other Invisicare international patents.

This patent approval is a significant milestone for Skinvisible as multi-national pharmaceutical and consumer goods companies seeking products for global distribution will now have protected products to license from Skinvisible on four continents, covering over twenty-two countries. Invisicare patent coverage now includes Europe, plus previously announced India, Australia, China, Japan, Hong Kong, Korea, Canada and the USA.

"We are excited about our international patent portfolio especially as it pertains to licensing our products globally, as well as the increase in value of our intellectual property and therefore our Company," said Mr. Terry Howlett, President and CEO of Skinvisible. "Patent protection provides Skinvisible and its licensees with a strong marketing advantage over other products using similar active ingredients. Additionally, Skinvisible continues to proactively build and strengthen its global intellectual property portfolio with twenty-eight patents pending, in addition to developing new Invisicare technologies for topical, transdermal and mucosal delivery." He added, "We expect to significantly reinforce our patent portfolio with new products in high-value disease areas, formulated with the next generation of Invisicare technologies."

Skinvisible formulates and licenses products in the areas of dermatology, women's health, pain management, surgical preparation, consumer health and others. In addition to these in-house developments, Skinvisible develops products for pharmaceutical companies seeking life cycle management for products coming off patent. Invisicare offers them a cost-effective new delivery vehicle and new patent protection thereby extending the sales life of their products.

Skinvisible is actively seeking partnering, licensing and co-development arrangements in both the United States and internationally.